Proctitis Clinical Trial
Official title:
A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to evaluate safety and tolerability of cyclically-dosed rectal budesonide foam in participants with active ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS).
This is a Phase 3, multicenter, open-label study in participants who previously participated in a Salix-sponsored budesonide rectal foam study for the treatment of UP or UPS. Approximately 300 participants were to be enrolled into the study and receive budesonide foam cyclically for 6 weeks (twice a day [BID] for 2 weeks and once daily [QD] for 4 weeks). The study was to continue until regulatory approval of budesonide foam occurred or the sponsor decided to terminate the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01966783 -
Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis
|
Phase 2 | |
| Completed |
NCT01008423 -
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
|
Phase 3 | |
| Completed |
NCT01008410 -
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
|
Phase 3 | |
| Terminated |
NCT01172444 -
Clinical Trial With Mesalamine 1g Suppositories
|
Phase 3 | |
| Completed |
NCT01837615 -
Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis
|
Phase 2 |